CCJ

Summary

Underweight CCJ at $98.74 — reduce exposure, do not add. The structural uranium demand story and fortress balance sheet are real, but they are outweighed by an extreme valuation (170x trailing P/E, ~860x TTM FCF) and weak near-term cash generation. Position sizing: trim existing exposure; no new capital. Key levels: $100–$102 immediate resistance, $105 (200-day SMA) as the trend-reversal trigger, $85–$90 support. A volume-backed break above $105 would shift the view bullish (reconsider adding); a break below $85 confirms the bearish lean (trim/exit). Time horizon: 5–10 trading days for re-evaluation. Consider covered calls or put spreads to harvest the elevated put skew while reducing exposure.

The case

The bull and bear cases are both real, but on balance the downside risk dominates at $98.74. The bull's strongest point is the structural demand shift — hyperscalers signing decade-long nuclear power deals — plus Cameco's scarcity premium as one of only two actual fuel suppliers, and a strong balance sheet ($1.1B cash vs ~$1B debt). The bear's strongest point is the valuation: 170x trailing earnings, ~860x TTM FCF, 8.4x book, negative operating cash flow (-$22.3M) and negative FCF (-$100M) in the most recent quarter. The single most important nuance is the contract-driven revenue argument: Cameco sells much of its uranium under long-term contracts struck at lower prices, so decade-high spot prices do not immediately flow to the bottom line — this explains the 9.1% operating margin and the Q2 earnings miss despite the bullish narrative. It also explains why the "Westinghouse equity income is real cash" claim is weak: that line swung from +$188.4M to -$16.3M in consecutive quarters, indicating mark-to-market volatility, not stable cash generation. The technical picture is a bear-market recovery (price below the 200-day SMA, 50 SMA below 200 SMA) with decisively bearish options flow (put/call volume 2.48, OI 3.24). Our analysis finds that high-beta names held through directional swings often miss the move, but CCJ's extreme valuation and weak near-term cash flow distinguish it from momentum names — the downside risk from a Fed-driven multiple compression is real. The bearish options flow and death-cross structure, combined with the valuation and cash-flow weakness, justify an Underweight despite the balance-sheet floor and genuine long-term demand. This is a committed Underweight, not a hedge.

What would weaken it

• Extreme valuation: 170x trailing P/E, ~860x TTM FCF
• Weak near-term cash generation: negative operating cash flow and FCF
• Fed-driven multiple compression on a high-beta name